Afferent Corp.
This article was originally published in Start Up
Executive Summary
With a device that boosts the sensitivity of certain sensors in the skin known as mechanoreceptors, Afferent Corp. hopes to address the large unmet needs of elderly falls and diabetic neuropathy. Its external mechanoreceptor stimulation devices might also prove to be useful in the rehabilitation that patients undergo following stroke and sports injuries.
You may also be interested in...
Myomo Inc.
Myomo is capitalizing on the growing tide of scientific evidence that patients have the ability to recover motor function following neurological trauma, such as stroke. The first product from its NeuroRobotics platform is the e100 NeuroRobotic System, a lightweight robotic brace that slides onto the arm and helps improve the patient's mobility by enabling him to initiate and control movement of partially paralyzed muscles by using his own biological signals.
Afferent Strikes a Good Deal with Stryker
In January, Stryker made an equity investment in neurostimulation start-up Afferent, operating in stroke rehabilitation. The deal is part of Stryker's growth plans to invest in emerging markets that are adjacent to core business segments. For Afferent, the partnership is validation of its unique platform, which stimulates afferent (incoming) rather than efferent (outgoing) nerve centers.
Start-Up News February 2007
A brief discussion of a few new companies in stroke management and prevention.